source
- Cure for HIV must protect long-term survivors from loss of benefitsThe authors, a postdoctoral researcher, a long‑term HIV survivor, and the head of a survivor alliance, argue that a future HIV cure should not jeopardize the support systems that have kept many pat…
- Novo Nordisk launches Phase 3 trial of lower maintenance doses of oral Wegovy for obesityNovo Nordisk has begun a Phase 3, placebo-controlled study called OASIS 5 to evaluate two lower oral doses of its GLP-1 weight-loss drug Wegovy (semaglutide) in people who are obese or overweight.…